VitaPro Peptides
Keep the sources close to the claim
These are the papers and FDA pages used here. The notes explain why each is on the list and where its answer stops.
Follow the MOTS-c experiments
The first MOTS-c paper — Lee’s group, Cell Metabolism (2015). Describes the sixteen-amino-acid peptide and experiments in cells and mice. Neither the sequence nor the animal results establish a human treatment benefit.
The cell-stress study — Kim’s group, Cell Metabolism (2018). Follows MOTS-c into the nucleus of stressed cells and examines gene activity. The physical-performance study — Reynolds’ team, Nature Communications (2021). Gives MOTS-c to mice and observes human peptide levels after exercise. These are different kinds of evidence.
A human trial record is not a result
The registered MOTS-c trial includes adults with prediabetes who also have overweight or obesity. The record checked in September 2026 listed it as recruiting, with no posted results. That record cannot tell us what participants experienced.
The animal findings are worth understanding with the animal part attached.
NAD+ and its building materials
The NAD+ metabolism review — A. J. Covarrubias led this 2021 review in Nature Reviews Molecular Cell Biology. It explains the molecule’s cellular work. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors: materials cells use to make NAD+.
The oral NR trial — Conze’s group, Scientific Reports (2019). Studies healthy adults with overweight and reports higher whole-blood NAD+. The oral NMN muscle trial — Yoshino’s group, Science (2021). The participants had prediabetes and were past menopause. Their muscles responded better to insulin. Body composition stayed unchanged. HbA1c, reflecting blood sugar over a longer stretch, also stayed unchanged.
Walking and the wider picture
The NMN walking study — Yi’s team, GeroScience (2023). Reports better walking-test distances and quality-of-life scores. The human precursor review — Vinten’s group, Nature Metabolism (2025). Describes limited benefits overall and gaps in knowledge about different tissues.
Blood, muscle and walking results each tell us something different.
FDA pages answer safety and approval questions
FDA’s bulk-substance safety page lists MOTS-c as nominated but withdrawn. The page carries an April 22, 2026 date; individual withdrawals aren’t dated. Potential immune reactions are still a concern, alongside peptide impurities and a shortage of human safety information.
FDA’s answers about compounding explain why compounded preparations lack FDA approval. That tells us about approval. It cannot establish whether a particular treatment helps people.
Withdrawal doesn’t supply clearance
Taking back a nomination gives no permission to compound. Safety concerns remain. Keep that regulatory question separate from what happened in an experiment; each needs its own answer.
The home page brings the reading back to an ordinary afternoon.